This issue was first brought to my attention by John De Castro. Since their main research focus is the glial cell, a cell that resembles the brain equivalent of a macrophage, I was immediately interested. They have a respected research effort bridging two hot areas.... inhibitors of complement activation and Alzheimer's. In addition, they have approved products that are beginning to produce revenues.
As most in this forum know, second and third tier biotechs got whacked in June/July. Many have not recovered, particularly those that were largely undiscovered in the first place. GLIA, PCYC and CIST are my current "weighted" picks among the undiscovered. However, at this time, I know less about GLIA research programs than I should. I would therefore appreciate any critical commentary. I'll follow this post with the latest earnings report.
Usual disclaimers apply, do your own homework.
Rick |
